Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moleculin Biotech, Inc. Director's Dealing 2019

Jul 15, 2019

34881_dirs_2019-07-15_623b7c74-921b-4f46-a4a9-5b4eeb2b3f50.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2019-07-11

Reporting Person: KLEMP WALTER V (Director, CEO and President)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-07-11 Stock option (right to buy) $1.31 A 500000 Acquired 2029-07-11 Common Stock (500000.0) Direct
2019-07-11 Restricted Stock Units $ A 316907 Acquired Common Stock (316907.0) Direct

Footnotes

F1: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.

F2: Issued in connection with the reporting person's employment with the Company.

F3: Each restricted stock unit represents a contingent right to receive one share of Company common stock.

F4: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.